



T: 0131-244-2528  
E: irene.fazakerley@gov.scot

**IMMEDIATE MESSAGE TO:**

1. Directors of Pharmacy
2. Medical Directors NHS Boards

25 June 2025

Dear Healthcare Professional,

**DRUG ALERT CLASS 3 – No 28 2025 – CLASS 3 MEDICINES RECALL – ACTION WITHIN 5 DAYS – IMMUNOCORE LTD – KIMMTRAK 200MCG/ML CONCENTRATE FOR SOLUTION FOR INFUSION**

Please see drug alert for onward transmission as below

Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Primary Care Pharmacists

Please could Medical Directors arrange to forward this alert on to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

**IRENE FAZAKERLEY**  
**Medicines Policy Team**





# MEDICINES RECALL

## CLASS 3 MEDICINES RECALL, EL(25)A/28

Action within 5 days

Issued 25 June 2025

Distribute to Pharmacy/Wholesaler Level

### MARKETING AUTHORISATION HOLDER (MAH)

Immunocore Limited

### MEDICINE DETAILS

**Kimmtrak 200 micrograms/ mL concentrate for solution for infusion**

PLGB: 36781/0001

Active Ingredient: tebentafusp

SNOMED code: 274087000

GTIN: 05056416800029

### AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
3D009AA17	31/03/2026	1 vial	08/2024
3D009AA19	31/03/2026	1 vial	10/2024
3D009AA36	31/03/2026	1 vial	12/2024
3D009AA39*	31/03/2026	1 vial	01/2025
3D009AA04*	31/03/2026	1 vial	09/2024

\* distributed in Northern Ireland only

### Background

Immunocore Limited is recalling the batches listed above as a precautionary measure. The recall is due to a decrease in potency identified during stability testing. All other stability test results remain within specification.

Only the batches listed in the above table are impacted. This does not affect other batches that are available.

#### Advice for Healthcare Professionals:

Stop supplying the impacted batches immediately. Quarantine all stock and return it to your supplier using your supplier's approved process. The batches listed in the table are being recalled as a precautionary measure.

#### Advice for Healthcare Professionals to Provide to Patients:

Patients who are taking Kimmtrak 200 micrograms/ mL concentrate for solution for infusion (tebentafusp) should continue to take the medication. This is a wholesale and pharmacy level recall that will be actioned by your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

#### Additional information:

For all medical information enquiries and information on this product, please email [medinfo.eu@immunocore.com](mailto:medinfo.eu@immunocore.com), or telephone +442076645100 (local toll) or +00 800-74451111 (toll-free).

For stock control enquiries please email [john.sandford@immunocore.com](mailto:john.sandford@immunocore.com), or telephone +00353(0)858515258.

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

**Defective Medicines Report Centre**  
**10 South Colonnade, Canary Wharf**  
**London, E14 4PU**

Telephone +44 (0)20 3080 6574  
[DMRC@mhra.gov.uk](mailto:DMRC@mhra.gov.uk)